project id: TCGA-PRAD; case submitter id: TCGA-EJ-A7NH; source center: 23; state: released; a260 a280 ratio: 1.85; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.18; rna integrity number: 7.8; age at index: 56; days to birth: -20734; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1957; age at diagnosis: 20734; ajcc clinical m: M0; ajcc clinical t: T2c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 474.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 230; initial weight: 210.0; sample id: f22e8b2d-68dd-4276-b57c-a068ced06ea5; sample submitter id: TCGA-EJ-A7NH-01A; portion id: 931c9a95-34db-45e5-b7a1-1761a3d75ea9; portion submitter id: TCGA-EJ-A7NH-01A-12; slide id: e744e068-a3a4-482a-91e2-b776980189b6; slide submitter id: TCGA-EJ-A7NH-01A-01-TSA; percent lymphocyte infiltration: 6.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 20.0; percent stromal cells: 45.0; percent tumor cells: 35.0; percent tumor nuclei: 75.0; section location: TOP;